Finding from a nationwide study of 5,000 participants that continues to evaluate existing drugs to treat mild-to-moderate COVID-19<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, July 14, 2022 (HealthDay News) — The asthma drug fluticasone furoate is yet another medication that does not work for mild-to-moderate COVID-19, a new study finds. The study was published online July 13 in medRxiv<\/em>, which publishes studies before they have been peer-reviewed.<\/p>\n “There was no evidence of improvement in time to recovery or reduction in hospitalizations in participants who took fluticasone furoate versus those who took a placebo,” lead researcher Adrian Hernandez, M.D., executive director of the Duke Clinical Research Institute in Durham, North Carolina, said in a Duke news release<\/a>.<\/p>\n The finding comes from a nationwide study of nearly 5,000 participants that continues to evaluate the potential benefit of existing drugs to treat mild-to-moderate COVID-19. Fluticasone furoate is one of three U.S. Food and Drug Administration-approved repurposed medications currently being tested against COVID-19.<\/p>\n Fluticasone furoate is an inhaled corticosteroid used to treat asthma, but it is not approved to treat COVID-19. This drug was tested because corticosteroids had seemed potentially beneficial for treating COVID-19 among nonhospitalized patients. Based on the findings, fluticasone furoate should not be used to treat COVID-19, the researchers stressed.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n